Pure Global AI
NCT05949333Not yet recruiting

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy
Eunseong Medical Foundation Good GANG-AN HOSPITALPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Breast Neoplasms
Drug/Device/Intervention
Eflapegrastim
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Location
Busan, South Korea
Timeline & enrollment
Phase
Phase 4
Start date
Aug 01, 2023
End date
Jan 01, 2025
Enrollment
100 participants
Primary outcome

Incidence rate of severe neutropenia Incidence rate of severe neutropenia

Summary

Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first
 round are randomly assigned to either the control or experimental arm. Patients in the
 control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm
 will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim
 administration date from day 1 to day 3 starting from the second round of chemotherapy could
 reduce the incidence of neutropenia

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedBenign neoplasm of breastMalignant neoplasm: Central portion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05949333
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05949333 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eunseong Medical Foundation Good GANG-AN HOSPITAL and is currently Not yet recruiting. The study focuses on Breast Neoplasms. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.